Effectiveness of IRK-19® on Body Weight Control

Greenyn Biotechnology

Status: Completed

Conditions: Overweight; Metabolic Syndrome

Treatments: Dietary Supplement: Pumpkin seed extract (IRK-19)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05542160

G-CAZ0040161110628-1

Details and patient eligibility

About

This randomized, double-blind, placebo-controlled, and parallel clinical study aims to investigate the effectivness of a pumpkin seed extract (IRK-19®) on weight management.

Enrollment: 50 patients

Sex: All

Ages: 20 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. BMI: 25-30 kg/m2
2. Waistline circumference: ˃ 80 cm

Exclusion criteria

1. Pregnant women or preparing for pregnancy.
2. Lactating women.
3. Women gave birth 6 months before the study.
4. Subject uses diuretic, corticosteroids, anti-depressant medications, or antipsychotic medications.
5. Subject has undertaken obesity-related surgeries within one year prior to the study or other surgeries within six months prior to the study.
6. Change of body weight of subject is over 5% within 3 months before the study.
7. Subject has serious diseases (e.g., cardiovascular diseases).
8. Cancer patient.
9. Subject has engaged in another study within 3 months before the study.
10. Subject uses another dietary supplement related to weight management during the study.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Placebo capsule

Treatment:

Dietary Supplement: Pumpkin seed extract (IRK-19)

Treatment

Experimental group

Description:

IRK-19 capsule

Treatment:

Dietary Supplement: Pumpkin seed extract (IRK-19)